BRCA2 and cancer: The seminal discovery of the ability of early PARP small molecule inhibitors, or PARP1 silencing, to selectively kill BRCA1- or BRCA2-deficient cells [23, 24], kickstarted the development of clinically approved PARPi, which have shown significant efficacy as monotherapy in HRR-deficient cancers [25].